Eledon Pharmaceuticals

ELDNPhase 2

Eledon Pharmaceuticals is dedicated to its mission of 'One Transplant for Life,' aiming to significantly improve the longevity of transplanted organs and the quality of life for recipients. The company's core asset, tegoprubart, targets the CD40 Ligand pathway, a key driver of immune-mediated rejection, and has completed a Phase 2 trial in kidney transplant. Eledon is strategically positioned in the high-need transplant immunosuppression market and is exploring applications in xenotransplantation and neurodegenerative diseases, leveraging its deep immunology expertise.

Market Cap

$229.3M

Focus

Small Molecules

ELDN · Stock Price

USD 2.881.02 (-26.15%)

Historical price data

AI Company Overview

Technology Platform

Platform focused on modulating the CD40/CD40 Ligand (CD40L) costimulatory pathway using monoclonal antibodies to induce immune tolerance and prevent rejection in transplantation and autoimmune diseases.

Pipeline Snapshot

9 drugs in pipeline

Drug	Indication	Stage
AT-1501 + Tacrolimus	Kidney Transplant Rejection	Phase 2
AT-1501	IgA Nephropathy	Phase 2
AT-1501	Amyotrophic Lateral Sclerosis	Phase 2
AT-1501 + Tacrolimus	Kidney Transplant Rejection	Phase 2
AT-1501	Type 1 Diabetes Mellitus	Phase 2

Opportunities

Major opportunities include disrupting the stagnant transplant immunosuppression market with a safer, more durable therapy, becoming a cornerstone immunosuppressant in the emerging field of xenotransplantation, and expanding into large autoimmune and neurodegenerative disease markets like ALS.

Successful partnerships could accelerate development across these areas.

Risk Factors

Key risks include clinical trial failures, regulatory hurdles for a new mechanism in a conservative market, challenges commercializing against low-cost generic standards of care, dependence on future financing, and the high-risk, experimental nature of the xenotransplantation field.

Competitive Landscape

Eledon competes against entrenched, generic calcineurin inhibitors (tacrolimus) and other companies developing novel immunosuppressants. Its differentiation lies in targeting the validated CD40L pathway with tegoprubart, aiming for better efficacy and a safer side-effect profile without lymphopenia, and its early-mover position in xenotransplantation immunosuppression.